New Risk • Mar 30
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: NT$301.4m (US$9.41m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Market cap is less than US$10m (NT$301.4m market cap, or US$9.41m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). 공시 • Mar 12
Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026 Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 09, 2026. Location: 1 floor no,26, k`un yang st., nangang district, taipei city Taiwan New Risk • Feb 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (NT$986.4m market cap, or US$31.3m). New Risk • Jan 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$1.29b market cap, or US$41.1m). New Risk • Aug 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$1m (NT$370k revenue, or US$12k). Minor Risk Market cap is less than US$100m (NT$986.4m market cap, or US$32.3m). New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$828.9m market cap, or US$25.1m). 공시 • Mar 13
Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025 Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 10, 2025. Location: 1 floor no,465-1, sec.6 chung hsiao e. rd., nangang district, taipei city Taiwan New Risk • Mar 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.08b market cap, or US$32.7m). 공시 • Mar 19
Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024 Eusol Biotech Co.,Ltd., Annual General Meeting, Jun 06, 2024. New Risk • Feb 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (5.7% average weekly change). Market cap is less than US$100m (NT$1.30b market cap, or US$41.2m). 공시 • Mar 06
EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022 EUSOL Biotech Co., Ltd., Annual General Meeting, May 20, 2022. 공시 • Mar 16
EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021 EUSOL Biotech Co., Ltd., Annual General Meeting, May 31, 2021. Is New 90 Day High Low • Mar 06
New 90-day low: NT$24.45 The company is down 11% from its price of NT$27.60 on 04 December 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Jan 28
New 90-day low: NT$24.65 The company is down 9.0% from its price of NT$27.10 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period. Is New 90 Day High Low • Jan 13
New 90-day low: NT$24.85 The company is down 3.0% from its price of NT$25.75 on 16 October 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period. Is New 90 Day High Low • Oct 12
New 90-day low: NT$24.50 The company is down 14% from its price of NT$28.35 on 14 July 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period. 